XML 50 R40.htm IDEA: XBRL DOCUMENT v3.19.2
Collaboration Agreements - Additional Information (Details)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Nov. 30, 2017
USD ($)
TargetAntigen
Milestone
Jun. 30, 2019
USD ($)
Jun. 30, 2018
USD ($)
Jun. 30, 2019
USD ($)
Jun. 30, 2018
USD ($)
Dec. 31, 2017
USD ($)
Merck Sharp & Dohme Corp.            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Service revenue recognized         $ 69,000  
Surface Oncology, Inc.            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Service revenue recognized     $ 63,000   125,000  
Number of target antigens against which antibodies are to be identified and selected | TargetAntigen 2          
Upfront fee to be received $ 250,000          
Number of designated milestones | Milestone 4          
Upfront payments fee received   $ 25,000 $ 64,000 $ 118,877 $ 133,000 $ 250,000
Surface Oncology, Inc. | Minimum            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Term of research program 9 months          
Surface Oncology, Inc. | Maximum            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Term of research program 12 months